Entering text into the input field will update the search result below

CureVac expands Phase 1 Trial for CV8102 in advanced Melanoma

Feb. 04, 2021 10:04 AM ETCureVac N.V. (CVAC) StockBy: Dulan Lokuwithana, SA News Editor
  • CureVac N.V. (NASDAQ:CVAC +5.2%) has announced the start of an expansion of the ongoing Phase 1 study for its RNA-based cancer drug candidate, CV8102, in patients with advanced melanoma.
  • With the expansion part involving 30 patients with PD-1 refractory melanoma, the company intends

Recommended For You

More Trending News

About CVAC Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CVAC--
CureVac N.V.